Navigation Links
2-drug combination appears safe and active in metastatic kidney cancer
Date:5/31/2009

ORLANDO (May 31, 2009)Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are less likely to respond to other targeted therapies.

Elizabeth Plimack, M.D., M.S., a medical oncologist and attending physician at Fox Chase will report the trial results on Sunday, May 31 at the annual meeting of the American Society of Clinical Oncology.

"We have certainly seen sustained responses with this combination which are encouraging," Plimack says.

One of the patients with an extended response has papillary renal cell cancer, which is a rare form of the disease that does not respond well to standard therapies. "Patients with non-clear cell renal cell cancer, including papillary renal cancer, don't respond as well to tyrosine kinase inhibitors, such as sunitinib and sorafenib, as patients with clear cell renal cell. So there is an unmet need for therapy for these patients. We've seen that this combination may be active to some degree for them."

mTOR signaling promotes tumor cell proliferation and blood vessel development. Temsirolimus (Torisel), blocks signaling through one portion of the mTOR signaling complex, called TORC1, and slows tumor progression in patients with advanced kidney cancer. However, a second portion of the complex, called TORC2, is unaffected by temsirolimus and continues to promote cell proliferation. Therefore, Plimack and colleagues suspect that blocking TORC2 signaling activity could improve patient outcomes. Bryostatin blocks a downstream effector of TORC2, called protein kinase C.

Plimack and colleagues designed the phase I trial to test the safety of the bryostatin-temsirolimus combination. Twenty-five patients enrolled in the trial, including 20 patients with renal cell carcinoma. The phase I trial tested a combination of 20 micrograms/m2 bryostatin weekly plus one of the following temsirolimus doses, 10, 15, 25, or 37.5 mg, every 28 days.

The combination appears to be well tolerated in renal cell patients. Two patients developed dose limiting toxicities (one with renal toxicity and one with neutropenia) at the highest temsirolimus dose. Enrollment is now continuing with patients receiving 25 mg temsirolimus. (Two of the non-renal cell cancer patients developed dose-limiting toxicities early in the trial, after which point the investigators limited enrollment to patients who had not received prior chemotherapy.)

Early responses in renal cell cancer patients are promising, according to Plimack. Three patients have had durable partial responses to therapy. Two of those individuals are off therapy and have partial responses continuing at 3+ years and 12+ months, and a third patient continues on therapy with a partial response extending beyond 22 months.

Enrollment in the trial is on-going and complete data will be provided at the meeting.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. 2-drug blood pressure therapy lowers cardiovascular risk
2. New treatment combination proves safe for head and neck cancer patients
3. Study shows drug combination improves outcome for advanced non-small cell lung cancer
4. Chemotherapy combination outcomes differ for aged, younger colon cancer patients
5. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
6. Transplant Surgery and Identity: A Discussion Among Pioneers with Unusual Combinations of Interests, Skills and Talents
7. Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
8. HealthWarehouse.com, Inc. Announces Completion of Business Combination With Clacendix, Inc.
9. Triple drug combination is promising option to treat metastatic HER2+ breast cancer
10. Plavix, Heartburn Drugs May Be Risky Combination
11. Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... to announce the ATA 2017 President’s Awards recipients, comprised of organizations and ... healthcare delivery. , The ATA 2017 President’s Awards recognize individuals and ...
(Date:4/26/2017)... ... April 26, 2017 , ... The National ... upon National Registry of Emergency Medical Technicians and welcomes this organization ... Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding ... more and better food, with fewer resources. It highlights the business’ principles, research ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a leader in ... a new class of photodynamic cosmetics (PDC). , Allumera® is the first PDC ... signs of aging, and minimize the appearance of pores – all with minimal ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment can hurt the physical ... productivity and performance in the workplace. The goal of Clearview Resolution Services has always ... of April, Clearview Resolution Services will be shutting down the office early on Fridays. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: